Clinical Trial Update: Atacicept Demonstrating Dose RESponSe [Phase 2]

View source ↗

Summary

A Phase 2 trial of atacicept for systemic lupus erythematosus, which had shown dose response, was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Atacicept (atacicept)

Snippet

Sponsor: EMD Serono | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: WITHDRAWN